HCPCS Level II code J9046 denotes a 0.1 mg unit of bortezomib (Dr. Reddy's), a parenteral oncology medication not therapeutically equivalent to J9041. Nationally, this code matters because it enables payers and providers to distinguish between manufacturers and formulations of a widely used proteasome inhibitor for hematologic malignancies, which can affect billing, inventory, and reimbursement pathways.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bortezomib use, the service setting where charges typically occur (outpatient infusion centers, hospital outpatient departments, and physician offices), and the implications of manufacturer-specific HCPCS coding.

This publication provides benchmarks and billing guidance context where available, highlights typical sites of service for administration, and summarizes common modifiers and coding considerations relevant to J9046. It also identifies gaps where input data was not provided. The goal is to give billing managers, practice administrators, and policy analysts a clear, national-level reference for handling claims that involve this specific bortezomib formulation.